montméd inc.

montméd is a Canadian company who brings simple and unique innovations that makes a difference in the daily life of people with diabetes. Our innovation is seamlessly integrated in the normal diabetes treatment routine to reduce the burden, while delivering superior results. Lack of diabetes injection site rotation is a well documented, well known problem. The impact on glycemic control and glycemic variability is quite important. The Injection Guidelines are clear: site rotation is a very important to help prevent lipohypertrophy in insulin users, a phenomenon which is present in up to 65% on people using insulin. montméd SiteSmart pen needle is a patent pending innovation, proudly developed in Canada. It aims at helping insulin users to easily adopt an injection site rotation routine and facilitate its implementation by integrating the education directly in the product design, through the lowest common denominator of human learning, association. Less thinking, less tracking: more doing, better outcomes.

• Employees 9
• Founded 2019
• Annual Revenue $9529000